SF3B4 Regulates Cellular Senescence and Suppresses Therapy-induced Senescence of Cancer Cells

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2024 Oct 28

PMID 39467623

Authors

Seungyeon Yang

Minbeom Ko

Soojung Claire Hur

Eun Kyung Lee

Seung Min Jeong

Affiliations

Soon will be listed here.

Abstract

Background/aim: Cellular senescence is a state in which cells permanently exit the cell cycle, preventing tumor growth, but it can also contribute to aging and chronic inflammation. Senescence induced by cancer therapies, known as therapy-induced senescence (TIS), halts cancer cell proliferation and prevents metastasis. TIS has been investigated as an important therapeutic approach that could minimize cytotoxicity effects. This study aimed to elucidate the role of splicing factor 3B subunit 4 (SF3B4) in cellular senescence and TIS in cancer cells.

Materials And Methods: β-galactosidase staining was used to examine senescence induction. SF3B4 and p21 expression were determined by RT-qPCR and western blot. Cell proliferation and cell death were evaluated.

Results: SF3B4 expression decreases in replicative senescent human fibroblasts and its knockdown induces senescence via a p21-dependent pathway. In A549 non-small cell lung cancer (NSCLC) cells, SF3B4 knockdown also increased senescence markers. Notably, SF3B4 overexpression mitigated doxorubicin-induced senescence in A549 cells.

Conclusion: SF3B4 regulates senescence, and this study highlights its potential as a therapeutic target for developing better cancer treatment strategies by leveraging TIS to suppress tumor growth and enhance treatment efficacy.

References

Saleh T, Bloukh S, Carpenter V, Alwohoush E, Bakeer J, Darwish S . Therapy-Induced Senescence: An "Old" Friend Becomes the Enemy. Cancers (Basel). 2020; 12(4). PMC: 7226427. DOI: 10.3390/cancers12040822. View

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

Cazzalini O, Scovassi A, Savio M, Stivala L, Prosperi E . Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res. 2010; 704(1-3):12-20. DOI: 10.1016/j.mrrev.2010.01.009. View

Zhang Y, Qian J, Gu C, Yang Y . Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021; 6(1):78. PMC: 7902610. DOI: 10.1038/s41392-021-00486-7. View

Yang S, Moon S, Hur S, Jeong S . Fatty acid oxidation regulates cellular senescence by modulating the autophagy-SIRT1 axis. BMB Rep. 2023; 56(12):651-656. PMC: 10761749. View

Hsu C, Altschuler S, Wu L . Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy. Cell. 2019; 178(2):361-373.e12. PMC: 6688629. DOI: 10.1016/j.cell.2019.05.041. View

Campisi J, dAdda di Fagagna F . Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8(9):729-40. DOI: 10.1038/nrm2233. View

Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

McHugh D, Gil J . Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2017; 217(1):65-77. PMC: 5748990. DOI: 10.1083/jcb.201708092. View

10.

Ewald J, Desotelle J, Wilding G, Jarrard D . Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010; 102(20):1536-46. PMC: 2957429. DOI: 10.1093/jnci/djq364. View

11.

Huang W, Hickson L, Eirin A, Kirkland J, Lerman L . Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol. 2022; 18(10):611-627. PMC: 9362342. DOI: 10.1038/s41581-022-00601-z. View

12.

Abbas T, Dutta A . p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9(6):400-14. PMC: 2722839. DOI: 10.1038/nrc2657. View

13.

Yang Z, Wang Y, Wen J, Gao H, Han Z, Qi J . SF3B4 promotes Twist1 expression and clear cell renal cell carcinoma progression by facilitating the export of KLF 16 mRNA from the nucleus to the cytoplasm. Cell Death Dis. 2023; 14(1):26. PMC: 9839716. DOI: 10.1038/s41419-022-05534-w. View

14.

Kim J, Park R, Kee Y, Jeong S, Ohn T . Splicing factor SRSF3 represses translation of p21 mRNA. Cell Death Dis. 2022; 13(11):933. PMC: 9640673. DOI: 10.1038/s41419-022-05371-x. View

15.

Kidogami S, Iguchi T, Sato K, Yoshikawa Y, Hu Q, Nambara S . Plays an Oncogenic Role in Esophageal Squamous Cell Carcinoma. Anticancer Res. 2020; 40(5):2941-2946. DOI: 10.21873/anticanres.14272. View

16.

Prasanna P, Citrin D, Hildesheim J, Ahmed M, Venkatachalam S, Riscuta G . Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst. 2021; 113(10):1285-1298. PMC: 8486333. DOI: 10.1093/jnci/djab064. View

17.

Xiong F, Li S . SF3b4: A Versatile Player in Eukaryotic Cells. Front Cell Dev Biol. 2020; 8:14. PMC: 7002316. DOI: 10.3389/fcell.2020.00014. View

18.

Kim B, Gwak J, Kim M, Yang S, Hwang S, Shin S . Suppression of fatty acid oxidation supports pancreatic cancer growth and survival under hypoxic conditions through autophagy induction. Cancer Gene Ther. 2023; 30(6):878-889. DOI: 10.1038/s41417-023-00598-y. View

19.

Lee J, Seo G, Hur W, Yoon S, Nam S, Lee J . SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells. Anticancer Res. 2020; 40(4):2033-2042. DOI: 10.21873/anticanres.14160. View

20.

Sun C . The SF3b complex: splicing and beyond. Cell Mol Life Sci. 2020; 77(18):3583-3595. PMC: 7452928. DOI: 10.1007/s00018-020-03493-z. View